Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Characterization of pediatric liver lesions with gadoxetate disodium.

Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ.

Pediatr Radiol. 2011 Sep;41(9):1183-97. doi: 10.1007/s00247-011-2148-6. Epub 2011 Jun 24.

PMID:
21701987
2.

Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver.

Ringe KI, Husarik DB, Sirlin CB, Merkle EM.

AJR Am J Roentgenol. 2010 Jul;195(1):13-28. doi: 10.2214/AJR.10.4392. Review.

PMID:
20566794
3.

Functional hepatobiliary MR imaging in children.

Tamrazi A, Vasanawala SS.

Pediatr Radiol. 2011 Oct;41(10):1250-8. doi: 10.1007/s00247-011-2086-3. Epub 2011 May 7.

PMID:
21553038
4.

Focal liver lesion detection and characterization with GD-EOB-DTPA.

Purysko AS, Remer EM, Veniero JC.

Clin Radiol. 2011 Jul;66(7):673-84. doi: 10.1016/j.crad.2011.01.014. Epub 2011 Apr 23. Review.

PMID:
21524416
5.

Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging.

Kim MJ, Rhee HJ, Jeong HT.

AJR Am J Roentgenol. 2012 Nov;199(5):W575-86. doi: 10.2214/AJR.11.8205. Review.

PMID:
23096201
6.

Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI--typical, atypical, pre- and post-treatment evaluation.

Meyers AB, Towbin AJ, Geller JI, Podberesky DJ.

Pediatr Radiol. 2012 Jul;42(7):859-66. doi: 10.1007/s00247-012-2366-6. Epub 2012 Mar 15. Review.

PMID:
22419052
7.

Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.

Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J.

Invest Radiol. 2011 Sep;46(9):556-66. doi: 10.1097/RLI.0b013e31821a218a.

PMID:
21623212
8.

Consensus report of the 2nd International Forum for Liver MRI.

Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L.

Eur Radiol. 2009 Oct;19 Suppl 5:S975-89. doi: 10.1007/s00330-009-1624-y.

PMID:
19851766
9.

Hepatobiliary transit times of gadoxetate disodium (Primovist®) for protocol optimization of comprehensive MR imaging of the biliary system--what is normal?

Ringe KI, Husarik DB, Gupta RT, Boll DT, Merkle EM.

Eur J Radiol. 2011 Aug;79(2):201-5. doi: 10.1016/j.ejrad.2010.03.008. Epub 2010 Mar 29.

PMID:
20347540
10.

Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma.

Schalkx HJ, van Stralen M, Coenegrachts K, van den Bosch MA, van Kessel CS, van Hillegersberg R, van Erpecum KJ, Verkooijen HM, Pluim JP, Veldhuis WB, van Leeuwen MS.

Eur Radiol. 2014 Sep;24(9):2146-56. doi: 10.1007/s00330-014-3275-x. Epub 2014 Jul 5.

PMID:
24996795
11.

Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver.

Cruite I, Schroeder M, Merkle EM, Sirlin CB.

AJR Am J Roentgenol. 2010 Jul;195(1):29-41. doi: 10.2214/AJR.10.4538. Review.

PMID:
20566795
12.

Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.

Kiryu S, Inoue Y, Watanabe M, Izawa K, Shimada M, Tojo A, Yoshikawa K, Ohtomo K.

Magn Reson Imaging. 2009 Jan;27(1):101-7. doi: 10.1016/j.mri.2008.05.015. Epub 2008 Jul 3.

PMID:
18599243
13.
14.

Pseudolesion of the liver observed on gadoxetate disodium-enhanced magnetic resonance imaging obtained shortly after transarterial chemoembolization for hepatocellular carcinoma.

Shinagawa Y, Sakamoto K, Fujimitsu R, Ida M, Urakawa H, Kora S, Higashihara H, Takano K, Yoshimitsu K.

Jpn J Radiol. 2010 Jul;28(6):483-8. doi: 10.1007/s11604-010-0454-9. Epub 2010 Jul 27.

PMID:
20661702
15.

Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.

Ringe KI, Hinrichs J, Merkle EM, Weismüller TJ, Wacker F, Meyer BC.

J Magn Reson Imaging. 2014 Jul;40(1):106-12. doi: 10.1002/jmri.24381. Epub 2013 Oct 31.

PMID:
24923477
16.

Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?

Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM.

J Magn Reson Imaging. 2012 Mar;35(3):611-6. doi: 10.1002/jmri.22850. Epub 2011 Oct 27.

PMID:
22034383
17.

Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, Fusté LC, Heinz-Peer G, Judmaier W, Laniado M, Manfredi RM, Mathieu DG, Müller D, Mortelè K, Reimer P, Reiser MF, Robinson PJ, Shamsi K, Strotzer M, Taupitz M, Tombach B, Valeri G, van Beers BE, Vogl TJ; European EOB-study group.

Eur Radiol. 2008 Mar;18(3):457-67. Epub 2007 Dec 6.

PMID:
18058107
18.

Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.

Nakamura Y, Date S, Toyota N, Tani C, Honda Y, Komoto D, Tanitame K, Awai K.

J Comput Assist Tomogr. 2011 May-Jun;35(3):351-2. doi: 10.1097/RCT.0b013e31821a02aa.

PMID:
21586929
19.

Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).

Motosugi U, Ichikawa T, Sou H, Sano K, Ichikawa S, Tominaga L, Araki T.

J Magn Reson Imaging. 2009 Oct;30(4):849-54. doi: 10.1002/jmri.21913.

PMID:
19787734
20.

Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.

Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM.

AJR Am J Roentgenol. 2011 Jan;196(1):W18-24. doi: 10.2214/AJR.10.4387.

PMID:
21178026

Supplemental Content

Support Center